Page last updated: 2024-12-06
tetrazolium violet
Description
Tetrazolium violet is a redox indicator that is commonly used in cell viability assays. It is a colorless compound that is reduced to a purple formazan dye by living cells, allowing for the quantification of cell proliferation and viability. The dye is typically used in conjunction with other dyes, such as MTT or XTT, to assess cell viability. Tetrazolium violet is a safe and reliable reagent for cell viability assays. It has been shown to be effective in a variety of cell types, including cancer cells, bacteria, and fungi. Tetrazolium violet is a widely used reagent in research and is particularly useful for studying cell proliferation, cell death, and drug efficacy. The compound is typically synthesized through a multi-step process that involves the reaction of aromatic amines with diazonium salts. The mechanism of action of tetrazolium violet involves the reduction of the tetrazolium ring by electron-donating molecules, such as NADH and NADPH, which are found in living cells. This reduction results in the formation of a purple formazan dye, which can be measured spectrophotometrically. The amount of formazan dye produced is directly proportional to the number of living cells in the sample. Tetrazolium violet is often used in conjunction with other assays, such as the MTT assay and the XTT assay, to assess cell viability. These assays are typically used to determine the cytotoxic effects of drugs, chemicals, or other agents on cells. Tetrazolium violet is a valuable tool for research in a variety of fields, including cancer biology, toxicology, and drug discovery.'
tetrazolium violet: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
tetrazolium violet : An organic chloride salt having tetrazolium violet(1+) as the counterion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 74395 |
CHEMBL ID | 272093 |
CHEBI ID | 75193 |
SCHEMBL ID | 134943 |
MeSH ID | M0524737 |
Synonyms (31)
Synonym |
1719-71-7 |
nsc-89171 |
nsc89171 |
LS-14981 |
tetrazolium violet |
tetrazolium purple |
violet tetrazolium |
einecs 217-008-7 |
nsc 89171 |
tv |
2,5-diphenyl-3(1-naphthyl)-2h-tetrazolium chloride |
2h-tetrazolium, 3-(1-naphthyl)-2,5-diphenyl-, chloride |
T-2600 |
CHEMBL272093 |
chebi:75193 , |
FT-0654502 |
2,5-diphenyl-3-(1-naphthyl)tetrazolium chloride |
T0174 |
3-(1-naphthyl)-2,5-diphenyl-2h-tetrazol-3-ium chloride |
AKOS015896126 |
SCHEMBL134943 |
mfcd00011875 |
tetrazolium violet, >=94% (at) |
3-(naphthalen-1-yl)-2,5-diphenyl-2h-tetrazol-3-ium chloride |
Q27145161 |
104117-26-2 |
DTXSID70938063 |
AMY39290 |
D92314 |
CS-0135937 |
HY-131490 |
Roles (3)
Role | Description |
dye | null |
apoptosis inducer | Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms. |
antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
organic chloride salt | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (4)
Assay ID | Title | Year | Journal | Article |
AID317434 | Antimalarial activity against Plasmodium falciparum in LDH reporter assay | 2008 | Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
| Anti-Plasmodium activity of tetrazolium salts. |
AID735073 | Displacement of SYBR green I from salmon testes DNA assessed as compound treated with DNA followed by SYBR green I added relative to control | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
| The interaction of imidazole-, imidazolium-, and tetrazolium-containing compounds with DNA. |
AID317436 | Ratio of IC50 for CHO cells to IC50 for Plasmodium falciparum | 2008 | Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
| Anti-Plasmodium activity of tetrazolium salts. |
AID317435 | Toxicity in CHO cells | 2008 | Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
| Anti-Plasmodium activity of tetrazolium salts. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 23.93
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 23.93 (24.57) | Research Supply Index | 2.08 (2.92) | Research Growth Index | 4.37 (4.65) | Search Engine Demand Index | 23.28 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |